275 related articles for article (PubMed ID: 36335531)
21. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
Braunwald E; Saberi S; Abraham TP; Elliott PM; Olivotto I
Eur Heart J; 2023 Nov; 44(44):4622-4633. PubMed ID: 37804245
[TBL] [Abstract][Full Text] [Related]
22. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
[TBL] [Abstract][Full Text] [Related]
23. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
[TBL] [Abstract][Full Text] [Related]
24. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
Chase Cole J; Benvie SF; DeLosSantos M
Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
[TBL] [Abstract][Full Text] [Related]
25. Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
Bertero E; Chiti C; Schiavo MA; Tini G; Costa P; Todiere G; Mabritto B; Dei LL; Giannattasio A; Mariani D; Lofiego C; Santolamazza C; Monda E; Quarta G; Barbisan D; Mandoli GE; Mapelli M; Sguazzotti M; Negri F; De Vecchi S; Ciabatti M; Tomasoni D; Mazzanti A; Marzo F; de Gregorio C; Raineri C; Vianello PF; Marchi A; Biagioni G; Insinna E; Parisi V; Ditaranto R; Barison A; Giammarresi A; De Ferrari GM; Priori S; Metra M; Pieroni M; Patti G; Imazio M; Perugini E; Agostoni P; Cameli M; Merlo M; Sinagra G; Senni M; Limongelli G; Ammirati E; Vagnarelli F; Crotti L; Badano L; Calore C; Gabrielli D; Re F; Musumeci G; Emdin M; Barbato E; Musumeci B; Autore C; Biagini E; Porto I; Olivotto I; Canepa M
Eur J Heart Fail; 2024 Jan; 26(1):59-64. PubMed ID: 38131253
[TBL] [Abstract][Full Text] [Related]
26. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
[TBL] [Abstract][Full Text] [Related]
27. Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M; Abbasi MA; Marar R; Geske JB; Gersh BJ; Anavekar NS
Curr Probl Cardiol; 2023 Jan; 48(1):101429. PubMed ID: 36167226
[TBL] [Abstract][Full Text] [Related]
28. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
[TBL] [Abstract][Full Text] [Related]
29. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Maron MS; Masri A; Choudhury L; Olivotto I; Saberi S; Wang A; Garcia-Pavia P; Lakdawala NK; Nagueh SF; Rader F; Tower-Rader A; Turer AT; Coats C; Fifer MA; Owens A; Solomon SD; Watkins H; Barriales-Villa R; Kramer CM; Wong TC; Paige SL; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Abraham T;
J Am Coll Cardiol; 2023 Jan; 81(1):34-45. PubMed ID: 36599608
[TBL] [Abstract][Full Text] [Related]
30. [Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment].
Lancellotti P; de Marneffe N; Scheen A
Rev Med Liege; 2024 Feb; 79(2):120-128. PubMed ID: 38356430
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
Dong T; Nissen S; Ospina S; Desai MY
Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review.
Yassen M; Changal K; Busken J; Royfman R; Schodowski E; Venkataramany B; Khouri SJ; Moukarbel GV
Am J Cardiol; 2024 Jan; 210():219-224. PubMed ID: 37884110
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of alcohol septal ablation in mildly symptomatic or severely symptomatic patients with hypertrophic obstructive cardiomyopathy].
Sun JJ; Li PJ; Yu XP; Zhao H; Zhang XL; Tu CC; Zhang MD; Jiang TY; Song XT; He JQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2023 May; 51(5):513-520. PubMed ID: 37198123
[No Abstract] [Full Text] [Related]
34. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy.
Dalo JD; Weisman ND; White CM
Ann Pharmacother; 2023 Apr; 57(4):489-502. PubMed ID: 35950315
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of mavacamten in patients with hypertrophic cardiomyopathy.
Liao HL; Liang Y; Liang B
J Cardiovasc Med (Hagerstown); 2024 Jul; 25(7):491-498. PubMed ID: 38814051
[TBL] [Abstract][Full Text] [Related]
36. A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy.
Burstein Waldman C; Owens A
Future Cardiol; 2021 Oct; 17(7):1269-1275. PubMed ID: 34018809
[TBL] [Abstract][Full Text] [Related]
37. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
Dong T; Alencherry B; Ospina S; Desai MY
Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
[TBL] [Abstract][Full Text] [Related]
38. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
[TBL] [Abstract][Full Text] [Related]
39. Mavacamten decreases maximal force and Ca
Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
